• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

MK-462在健康男性中的药代动力学及与食物的相互作用

Pharmacokinetics and food interaction of MK-462 in healthy males.

作者信息

Cheng H, Polvino W J, Sciberras D, Yogendran L, Cerchio K A, Christie K, Olah T V, McLoughlin D, James I, Rogers J D

机构信息

Merck Research Laboratories, West Point, PA 19486, USA.

出版信息

Biopharm Drug Dispos. 1996 Jan;17(1):17-24. doi: 10.1002/(SICI)1099-081X(199601)17:1<17::AID-BDD932>3.0.CO;2-F.

DOI:10.1002/(SICI)1099-081X(199601)17:1<17::AID-BDD932>3.0.CO;2-F
PMID:8991488
Abstract

A study was conducted to assess the safety, tolerability, and pharmacokinetics of single intravenous (IV) doses of 5-90 micrograms kg-1 of MK-462, and the effect of food on the pharmacokinetics of MK-462 administered orally to healthy males. Results of this study indicate that IV doses of MK-462 from 5 to 90 micrograms kg-1 are well tolerated. The disposition kinetics of MK-462 were linear for IV doses up to and including 60 micrograms kg-1. The values of the plasma clearance (CL), steady-state volume of distribution (Vss), plasma terminal half-life (t1/2), and mean residence time in the body (MRT) of MK-462 averaged 1376 mL min-1, 140 L, 1.8 h, and 1.7 h, respectively, and remained essentially constant over the dosage range of 10-60 micrograms kg-1 of IV MK-462. However, as the dose increased from 60 to 90 micrograms kg-1, the mean value of the apparent CL decreased from 1376 to 807 mL min-1. Thus, elimination of MK-462 was dose dependent in this dosage range. Based on the disposition decomposition analysis (DDA), it was shown that the Vss value of MK-462 remained essentially constant over the dosage range of 10-90 micrograms kg-1 of IV MK-462. The following values of two dose-independent parameters were also calculated by using DDA: distribution clearance (CLd) = 2028 mL min-1, and mean transit time in the peripheral tissues (MTTT) = 0.74 h. The mean values of AUC, Cmax, tmax, and apparent t1/2 of MK-462 in 12 subjects each receiving a 40 mg tablet of MK-462 without breakfast were 330 ng.h mL-1, 77 ng mL-1, 1.6 h, and 1.8 h, respectively. Although administration of a standard breakfast prior to dosing increased the AUC value (by approximately 20%) of MK-462 and delayed its absorption, there were no significant effects of the meal on the values of Cmax and apparent t1/2 of MK-462.

摘要

开展了一项研究,以评估单次静脉注射5 - 90微克/千克的MK - 462的安全性、耐受性和药代动力学,以及食物对健康男性口服MK - 462药代动力学的影响。该研究结果表明,静脉注射5至90微克/千克的MK - 462耐受性良好。对于高达并包括60微克/千克的静脉注射剂量,MK - 462的处置动力学呈线性。MK - 462的血浆清除率(CL)、稳态分布容积(Vss)、血浆末端半衰期(t1/2)以及在体内的平均驻留时间(MRT)的值分别平均为1376毫升/分钟、140升、1.8小时和1.7小时,并且在10 - 60微克/千克的静脉注射MK - 462剂量范围内基本保持恒定。然而,当剂量从60微克/千克增加到90微克/千克时,表观CL的平均值从1376降至807毫升/分钟。因此,在该剂量范围内,MK - 462的消除呈剂量依赖性。基于处置分解分析(DDA),结果显示在10 - 90微克/千克的静脉注射MK - 462剂量范围内,MK - 462的Vss值基本保持恒定。还通过使用DDA计算了两个非剂量依赖性参数的以下值:分布清除率(CLd)= 2028毫升/分钟,外周组织平均通过时间(MTTT)= 0.74小时。12名受试者每人服用一片40毫克的MK - 462且未吃早餐,MK - 462的AUC、Cmax、tmax和表观t1/2的平均值分别为330纳克·小时/毫升、77纳克/毫升、1.6小时和1.8小时。尽管在给药前食用标准早餐会增加MK - 462的AUC值(约20%)并延迟其吸收,但该餐食对MK - 462的Cmax和表观t1/2值没有显著影响。

相似文献

1
Pharmacokinetics and food interaction of MK-462 in healthy males.MK-462在健康男性中的药代动力学及与食物的相互作用
Biopharm Drug Dispos. 1996 Jan;17(1):17-24. doi: 10.1002/(SICI)1099-081X(199601)17:1<17::AID-BDD932>3.0.CO;2-F.
2
Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.二肽基肽酶-IV抑制剂西他列汀多次口服给药的药代动力学和药效学特性:一项在健康男性志愿者中进行的双盲、随机、安慰剂对照研究
Clin Ther. 2006 Jan;28(1):55-72. doi: 10.1016/j.clinthera.2006.01.015.
3
Pharmacokinetics of rizatriptan in healthy elderly subjects.利扎曲普坦在健康老年受试者中的药代动力学。
Int J Clin Pharmacol Ther. 2001 Oct;39(10):447-52.
4
Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females.孟鲁司特钠(MK - 0476)在健康男性和女性中的药代动力学、生物利用度及安全性。
Pharm Res. 1996 Mar;13(3):445-8. doi: 10.1023/a:1016056912698.
5
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses.二肽基肽酶IV抑制剂西他列汀在健康受试者中的药代动力学和药效学:两项单次口服剂量随机、双盲、安慰剂对照研究的结果
Clin Pharmacol Ther. 2005 Dec;78(6):675-88. doi: 10.1016/j.clpt.2005.09.002.
6
Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.口服二肽基肽酶-4抑制剂西他列汀在健康志愿者中的绝对生物利用度。
Biopharm Drug Dispos. 2007 Sep;28(6):315-22. doi: 10.1002/bdd.560.
7
Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humans.抗偏头痛药物利扎曲普坦在人体内的处置与药代动力学
Drug Metab Dispos. 2000 Jan;28(1):89-95.
8
Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.在两项针对健康志愿者的研究以及两项针对慢性肾病患者的研究中,δ-促红细胞生成素的药代动力学和药效学。
Clin Ther. 2007 Jul;29(7):1368-80. doi: 10.1016/j.clinthera.2007.07.014.
9
Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.卢非酰胺:癫痫患者的临床药代动力学及浓度-效应关系
Epilepsia. 2008 Jul;49(7):1123-41. doi: 10.1111/j.1528-1167.2008.01665.x.
10
Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.盐酸度洛西汀肠溶片在中国健康志愿者中的药代动力学:一项随机、开放标签、单剂量和多剂量研究。
Clin Ther. 2009 May;31(5):1022-36. doi: 10.1016/j.clinthera.2009.05.005.

引用本文的文献

1
Physicochemical properties of dietary phytochemicals can predict their passive absorption in the human small intestine.膳食植物化学物的物理化学性质可以预测其在人体小肠中的被动吸收。
Sci Rep. 2017 May 16;7(1):1931. doi: 10.1038/s41598-017-01888-w.
2
Rizatriptan in the treatment of migraine.利扎曲普坦治疗偏头痛。
Neuropsychiatr Dis Treat. 2006 Sep;2(3):247-59. doi: 10.2147/nedt.2006.2.3.247.
3
Rizatriptan: an update of its use in the management of migraine.利扎曲普坦:偏头痛治疗应用的最新进展
Drugs. 2002;62(10):1539-74. doi: 10.2165/00003495-200262100-00007.
4
Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review.曲坦类抗偏头痛药物的药代动力学和药效学:比较性综述。
Clin Pharmacokinet. 2001;40(3):189-205. doi: 10.2165/00003088-200140030-00004.
5
Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy.曲坦类药物治疗偏头痛:药理学、药代动力学及疗效的比较综述
Drugs. 2000 Dec;60(6):1259-87. doi: 10.2165/00003495-200060060-00003.
6
Rizatriptan: a review of its efficacy in the management of migraine.利扎曲普坦:偏头痛治疗疗效综述
Drugs. 1999 Oct;58(4):699-723. doi: 10.2165/00003495-199958040-00013.
7
Effects of food on clinical pharmacokinetics.食物对临床药代动力学的影响。
Clin Pharmacokinet. 1999 Sep;37(3):213-55. doi: 10.2165/00003088-199937030-00003.
8
Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers.口服利扎曲普坦在健康男性和女性志愿者中的药代动力学及耐受性
Br J Clin Pharmacol. 1999 Apr;47(4):373-8. doi: 10.1046/j.1365-2125.1999.00917.x.